After bidding war, Cambridge gene therapy firm Dimension accepts $151M buyout – Boston Business Journal
Boston Business Journal |
After bidding war, Cambridge gene therapy firm Dimension accepts $151M buyout
Boston Business Journal After weighing buyout offers from two out-of-state biotechs, Cambridge gene therapy firm Dimension Therapeutics said Tuesday that it has accepted the superior proposal — a $151 million deal that will allow the company to maintain a local presence. Shoving Regenxbio aside, Ultragenyx's Emil Kakkis closes Dimension buyout deal with 400% premium In RARE news, Dimension dumps Regenxbio for better offer Ultragenyx to Acquire Dimension Therapeutics |
